ADAM	a disintegrin and metalloprotease
AF	atrial fibrillation
AXIOMATIC-SSP	Antithrombotic treatment with Factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention
AVERT	A Very Early Rehabilitation Trial after stroke
BARC	Bleeding Academic Research Consortium
CAT	cancer-associated thrombosis
CCL 16	chemokine ligand 16
CD28	cluster of differentiation 28
CI	confidence interval
CTEPH	chronic thromboembolic pulmonary hypertension
DVP	deep-venous thrombosis
DOACs	direct oral anticoagulants
FII	factor II
FIII	factor III
FIX	factor IX
FOX-TROT	Fluoropyrimidine Oxaliplatin and Targeted Receptor Pre-Operative Therapy
FV	factor V
FVIIa	activated factor VII
FVIII	factor VIII
FX	factor X
FXI-ASO	Active Comparator-Controlled Study to Assess Safety and Efficacy of ISIS-FXIRx in Total Knee Arthroplasty
FXI	factor XI
FXII	factor XII
FXIIa	activated factor XII
FXa	activated factor X
GSDMD	gasdermin D
IL-1β	interleukin-1β
IR	incidence rate
LMWHs	low molecular weight heparin
LRR	leucine-rich repeats
MAPK	mitogen-activated protein kinase
NACHT	nucleotide-binding domain function
NLRP3	pyrin domain–containing protein 3
PAI-1	plasminogen activator inhibitor-1
PE	pulmonary embolism
PT	prothrombin time
PTS	post-thrombotic syndrome
PTT	partial thromboplastin time
TF	tissue factor
TNF-α	tumor necrosis factor-α
VE-cadherin	vascular endothelial cadherin
VLDLR	very low–density lipoprotein receptor
VTE	venous thromboembolism
vWF	von Willebrand factor